Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance prediction

20 Apr 2023

Abstract excerpt

The advances in scientific knowledge on biological therapies of the last two decades have impressively oriented the clinical management of non-small-cell lung cancer (NSCLC) patients. The treatment with tyrosine kinase inhibitors (TKIs) in patients harboring Epidermal Growth Factor Receptor ( EGFR )-activating mutations is dramatically associated with an improvement in disease control. Anyhow, the prognosis for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37152062
DOI: 10.3389/fonc.2023.1137384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance predictionPMID 37152062Read ↗

Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations.Semantic proximity Read ↗

Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patientsSemantic proximity Read ↗

The role of DNA methylation and DNA methyltransferases (DNMTs) as potential biomarker and therapeutic target in non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with SotorasibSemantic proximity Read ↗

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung AdenocarcinomaSemantic proximity Read ↗

Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

DNA methylation and nonsmall cell lung cancer.Semantic proximity Read ↗

Impact of DNA methylation on the recurrence risk of stage I non-small cell lung cancer with EGFR mutationsSemantic proximity Read ↗

Epigenetic biomarkers in lung cancer.Semantic proximity Read ↗

Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.Semantic proximity Read ↗

DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical managementSemantic proximity Read ↗

Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.